Mike Camilla
Vice President, Investor Relations at Abbott
Replay available
Abbott Laboratories (NYSE: ABT) Q2 2026 earnings conference call, held 2026-07-16. Replay captured from the company's public earnings webcast.

Vice President, Investor Relations at Abbott
Chairman and Chief Executive Officer at Abbott
Executive Vice President, Finance and Chief Financial Officer at Abbott
at JPMorgan
at Wells Fargo
at Evercore ISI
at Jefferies
at BoA Securities
at TD Cowen
at Citi
at BTIG
Good morning, and thank you for standing by. Welcome to Abbott's Second Quarter twenty twenty six Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star one one keys on your touch tone phone. This call is being recorded by Abbott. With the exception of any participants' questions asked during the question and answer session, the entire call, including the question and answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Camilla, Vice President, Investor Relations. Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer and Phil Boudreaux, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2026. Abbott cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10 ks for the year ended 12/31/2025. Abbott undertakes no obligation to release publicly any revisions to forward looking statements as a result of subsequent events or developmen...